CLAIMS

~~1. A dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size, wherein said liquid comprises between about 0.3 mg and about 0.9 mg of a siNA comprising SEQ ID NO. 3 and optionally one or more pharmaceutically acceptable diluents and optionally one or more excipients.~~

~~2. A dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size, wherein said liquid comprises between about 0.3 mg and about 0.9 mg of a siRNA comprising SEQ ID NO: 2 in a solution comprising phosphate buffered saline at a concentration of between about 7.5 mg/ml and about 22.5 mg/ml.~~

~~3. A kit comprising:~~

~~(a) a dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size; and~~

~~(b) written instructions specifying that between about 0.3 mg and about 0.9 mg of an siNA comprising SEQ ID NO: 1 in the form of one droplet is to be applied to each eye.~~

~~4. A kit comprising:~~

~~(a) a dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size; and~~

~~(b) written instructions specifying that between about 0.3 mg and about 0.9 mg of a siRNA comprising SEQ ID NO: 2 in a final concentration of between about~~

~~7.5 mg/ml and about 22.5 mg/ml in PBS in the form of one droplet is to be applied to each eye.~~

~~5~~1. The use of a short interfering nucleic acid molecule (siNA) comprising the nucleotide sequence of SEQ ID NO: 3 in the manufacture of a medicament for the treatment of an eye disorder characterized by increased intraocular pressure (IOP) wherein said siNA is for topical administration~~topically administered~~ to the corneal surface of the eye of a patient in need thereof at a dose of between about 0.3 mg and about 0.9 mg.

~~6~~2. Use of between about 0.3 mg and 0.9 mg of a siRNA comprising SEQ ID NO: 2 in phosphate buffered saline (PBS) in the manufacture of a medicament for the treatment of an eye disorder characterized by increased intraocular pressure (IOP) wherein said medicament is ~~topically administered~~for topical administration to the corneal surface of the eye of a patient in need thereof.

~~7~~3. Use of claim ~~5~~1, wherein the siNA is administered once per day.

~~8~~4. Use of claim ~~5~~1, wherein the siNA is delivered in a volume of between about 30 µl and about 40 µl.

~~9~~5. Use of claim ~~5~~1, wherein the siNA is delivered to the eye with an eyedropper.

~~10~~6. Use of claim ~~5~~1, wherein the siNA is short interfering ribonucleic acid (siRNA).

~~11~~7. Use of claim ~~10~~6, wherein the siRNA is double stranded RNA (dsRNA).

~~12~~8. Use of claim ~~10~~6, wherein the siRNA is short hairpin RNA (shRNA).

~~13~~9. Use of claim ~~5~~1, wherein the siNA comprises at least one modified oligonucleotide.

~~14~~10. Use of claim ~~5~~1, wherein the siNA comprises at least one linkage between two nucleotides that is not a phosphodiester linkage.

~~15~~11. Use of claim ~~5~~1, wherein the eye disorder is selected from the group consisting of open angle glaucoma, angle closure glaucoma, and congenital glaucoma.

~~16~~12. Use of claim ~~5~~1, wherein the siNA is 40 nucleotides or fewer.

~~17~~13. Use of claim ~~10~~6, wherein the siRNA is hybridised to its complement to make a dsRNA.

~~18~~14. Use of claim ~~11~~7, wherein the dsRNA has a dinucleotide 3' overhang.

~~19~~15. Use of claim ~~18~~14, wherein the dinucleotide 3' overhang is made of thymidine nucleotides.

~~20~~16. Use of claim ~~5~~1, wherein more than one type of siNA is administered to the patient.

~~21~~17. Use of claim ~~20~~16, wherein the more than one type of siNA decreases or inhibits the expression of the same gene.

~~22~~18. Use of claim ~~5~~1, wherein said siNA is unmodified.